Literature DB >> 21629258

Cerebral glucose utilisation in hepatitis C virus infection-associated encephalopathy.

Meike Heeren1, Karin Weissenborn, Dimitrios Arvanitis, Martin Bokemeyer, Annemarie Goldbecker, Argyro Tountopoulou, Thomas Peschel, Julian Grosskreutz, Hartmut Hecker, Ralph Buchert, Georg Berding.   

Abstract

Patients with hepatitis C virus (HCV) infection frequently show neuropsychiatric symptoms. This study aims to help clarify the neurochemical mechanisms behind these symptoms and to add further proof to the hypothesis that HCV may affect brain function. Therefore, 15 patients who reported increasing chronic fatigue, mood alterations, and/or cognitive decline since their HCV infection underwent neurologic and neuropsychological examination, magnetic resonance imaging, (18)F-fluoro-deoxy-glucose positron emission tomography of the brain, and single photon emission tomography of striatal dopamine and midbrain serotonin transporter (SERT) availability. None of the patients had liver cirrhosis. Patients' data were compared with data of age-matched controls. In addition, regression analysis was performed between cognitive deficits, and mood and fatigue scores as dependent variables, and cerebral glucose metabolism, dopamine, or SERT availability as predictors. Patients showed significant cognitive deficits, significantly decreased striatal dopamine and midbrain SERT availability, and significantly reduced glucose metabolism in the limbic association cortex, and in the frontal, parietal, and superior temporal cortices, all of which correlated with dopamine transporter availability and psychometric results. Thus, the study provides further evidence of central nervous system affection in HCV-afflicted patients with neuropsychiatric symptoms. Data indicate alteration of dopaminergic neurotransmission as a possible mechanism of cognitive decline.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21629258      PMCID: PMC3210344          DOI: 10.1038/jcbfm.2011.82

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  36 in total

Review 1.  Brain imaging of attentional networks in normal and pathological states.

Authors:  D Fernandez-Duque; M I Posner
Journal:  J Clin Exp Neuropsychol       Date:  2001-02       Impact factor: 2.475

2.  European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands.

Authors:  K Tatsch; S Asenbaum; P Bartenstein; A Catafau; C Halldin; L S Pilowsky; A Pupi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10       Impact factor: 9.236

3.  European Association of Nuclear Medicine procedure guidelines for brain imaging using [(18)F]FDG.

Authors:  P Bartenstein; S Asenbaum; A Catafau; C Halldin; L Pilowski; A Pupi; K Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10       Impact factor: 9.236

4.  Fatigue in patients with chronic hepatitis C.

Authors:  T Poynard; P Cacoub; V Ratziu; R P Myers; M H Dezailles; A Mercadier; P Ghillani; F Charlotte; J C Piette; J Moussalli
Journal:  J Viral Hepat       Date:  2002-07       Impact factor: 3.728

5.  Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment.

Authors:  H L Tillmann; M Wiese; Y Braun; J Wiegand; S Tenckhoff; J Mössner; M P Manns; K Weissenborn
Journal:  J Viral Hepat       Date:  2011-04       Impact factor: 3.728

Review 6.  Course and outcome of hepatitis C.

Authors:  Jay H Hoofnagle
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

7.  Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease.

Authors:  Daniel M Forton; Howard C Thomas; Christine A Murphy; Joanna M Allsop; Graham R Foster; Janice Main; Keith A Wesnes; Simon D Taylor-Robinson
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

Review 8.  [Memory and brain--neurobiological correlates of memory disturbances].

Authors:  P Calabrese; H J Markowitsch
Journal:  Fortschr Neurol Psychiatr       Date:  2003-04       Impact factor: 0.752

9.  Regional cerebral glucose utilization in patients with a range of severities of unipolar depression.

Authors:  Tim A Kimbrell; Terence A Ketter; Mark S George; John T Little; Brenda E Benson; Mark W Willis; Peter Herscovitch; Robert M Post
Journal:  Biol Psychiatry       Date:  2002-02-01       Impact factor: 13.382

10.  [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.

Authors:  G Berding; Th Brücke; P Odin; D J Brooks; H Kolbe; P Gielow; H Harke; B O Knoop; R Dengler; W H Knapp
Journal:  Nuklearmedizin       Date:  2003-02       Impact factor: 1.379

View more
  16 in total

1.  S100B and Inflammatory Cytokine Levels in Blood as Potential Markers of Blood-Brain Barrier Damage and Psychiatric Impairment in Comorbid Hepatitis C Viral Infection and Alcohol Use Disorder.

Authors:  Jennifer M Loftis; Juno Valerio; Jonathan Taylor; Elaine Huang; Rebekah Hudson; Patricia Taylor-Young; Michael Chang; Samuel B Ho; Eric Dieperink; Juan Luis Miranda; Peter Hauser
Journal:  Alcohol Clin Exp Res       Date:  2018-06-28       Impact factor: 3.455

Review 2.  Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview.

Authors:  Luigi Elio Adinolfi; Riccardo Nevola; Giacomo Lus; Luciano Restivo; Barbara Guerrera; Ciro Romano; Rosa Zampino; Luca Rinaldi; Ausilia Sellitto; Mauro Giordano; Aldo Marrone
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

3.  Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency.

Authors:  David A Sheridan; S H Bridge; M M E Crossey; D J Felmlee; H C Thomas; R D G Neely; S D Taylor-Robinson; M F Bassendine
Journal:  Metab Brain Dis       Date:  2014-03-12       Impact factor: 3.584

4.  Neuroinvasion and cognitive impairment in comorbid alcohol dependence and chronic viral infection: An initial investigation.

Authors:  Jennifer M Loftis; Jonathan Taylor; Rebekah Hudson; Evan J Firsick
Journal:  J Neuroimmunol       Date:  2019-07-10       Impact factor: 3.478

5.  Cerebral patterns of neuropsychological disturbances in hepatitis C patients.

Authors:  Tino Prell; Meike Dirks; Dimitrios Arvanitis; David Braun; Thomas Peschel; Hans Worthmann; Ramona Schuppner; Peter Raab; Julian Grosskreutz; Karin Weissenborn
Journal:  J Neurovirol       Date:  2019-01-04       Impact factor: 2.643

6.  Delay discounting is greater among drug users seropositive for hepatitis C but not HIV.

Authors:  Eileen Martin; Raul Gonzalez; Jasmin Vassileva; Antoine Bechara
Journal:  Neuropsychology       Date:  2015-05-18       Impact factor: 3.295

Review 7.  Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.

Authors:  Salvatore Monaco; Sara Mariotto; Sergio Ferrari; Massimiliano Calabrese; Gianluigi Zanusso; Alberto Gajofatto; Domenico Sansonno; Franco Dammacco
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 8.  Hepatitis C virus and neurological damage.

Authors:  Shilu Mathew; Muhammed Faheem; Sara M Ibrahim; Waqas Iqbal; Bisma Rauff; Kaneez Fatima; Ishtiaq Qadri
Journal:  World J Hepatol       Date:  2016-04-28

Review 9.  Depression, fatigue and neurocognitive deficits in chronic hepatitis C.

Authors:  Sern Wei Yeoh; Alex C N Holmes; Michael M Saling; Ian P Everall; Amanda J Nicoll
Journal:  Hepatol Int       Date:  2018-06-21       Impact factor: 6.047

Review 10.  HCV-related nervous system disorders.

Authors:  Salvatore Monaco; Sergio Ferrari; Alberto Gajofatto; Gianluigi Zanusso; Sara Mariotto
Journal:  Clin Dev Immunol       Date:  2012-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.